Erudio Healtherudio.com
Drug
Palbociclib trials: what clinicians said in public
No HCP commentary report on a trial studying palbociclib yet. Erudio has found public clinician commentary on 22 clinical trials studying palbociclib, including INAVO120, PALLAS, PATINA and VIKTORIA-1. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PATINA NCT02947685 · Alliance Foundation Trials, LLC. DeepView → | hormone receptor-positive, HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| VIKTORIA-1 NCT05501886 · Celcuity Inc DeepView → | HR+/HER2- advanced breast cancer after CDK4/6 inhibitor therapy | Phase 3 | Deep | View | |||
| INAVO120 NCT04191499 · Hoffmann-La Roche DeepView → | PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer | Phase 2/Phase 3 | Deep | View | |||
| PALLAS NCT02513394 · Alliance Foundation Trials, LLC. DeepView → | HR+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| PADA-1 NCT03079011 · UNICANCER DeepView → | ER-positive, HER2-negative metastatic breast cancer with ESR1 mutation | Phase 3 | Deep | View | |||
| SERENA-4 NCT04711252 · AstraZeneca DeepView → | ER-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| persevERA NCT04546009 · Hoffmann-La Roche DeepView → | Not given | Phase 3 | Deep | View | |||
| CodeBreaK 101 NCT04185883 · Amgen DeepView → | KRAS G12C-mutated advanced solid tumors | Phase 1 | Deep | View | |||
| SERENA-6 NCT04964934 · AstraZeneca DeepView → | ESR1-mutated ER-positive HER2-negative metastatic breast cancer | Phase 3 | Deep | View | |||
| ROME NCT04591431 · Fondazione per la Medicina Personalizzata DeepView → | advanced solid tumors | Phase 2 | Deep | View | |||
| DARE NCT04567420 · Criterium, Inc. DeepView → | estrogen receptor positive, HER-2 negative breast cancer | Phase 2 | Deep | View | |||
| CAPItello-292 NCT04862663 · AstraZeneca DeepView → | HR+/HER2- advanced breast cancer | Phase 3 | Deep | View | |||
| PALMIRA NCT03809988 · MedSIR DeepView → | hormone receptor-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| FourLight-3 NCT06760637 · Pfizer DeepView → | HR-positive HER2-negative advanced/metastatic breast cancer | Phase 3 | Deep | View | |||
| LITESPARK-024 NCT05468697 · Merck Sharp & Dohme LLC StandardView → | advanced renal cell carcinoma | Phase 1/Phase 2 | Standard | View | |||
| TRAK-ER NCT04985266 · Royal Marsden NHS Foundation Trust StandardView → | ER-positive HER2-negative breast cancer with molecular relapse | Phase 2 | Standard | View | |||
| EvoPAR-Breast01 NCT06380751 · AstraZeneca StandardView → | first-line BRCA1/BRCA2/PALB2-mutated HR-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||
| HERKULES-3 NCT05039177 · Erasca, Inc. FocusedView → | metastatic colorectal cancer or pancreatic ductal adenocarcinoma | Phase 1/Phase 2 | Focused | View | |||
| VERITAC-3 NCT05909397 · Pfizer FocusedView → | Not given | Phase 3 | Focused | View | |||
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche FocusedView → | metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT06377852 NCT06377852 · American Society of Clinical Oncology FocusedView → | metastatic breast cancer | Phase 3 | Focused | View | |||
| PELOPS NCT02764541 · Dana-Farber Cancer Institute FocusedView → | early invasive lobular or ductal breast cancer | Phase 2 | Focused | View | |||